In cutaneous solid tumors, the CADM1 promoter is highly methylated in cutaneous melanoma and is also associated with the advance of the tumor stage and disease-related survival methylation, suggesting that CADM1 is an indicator for poor prognoses of melanoma [34]. Here, CADM1 is linked to cutaneous melanoma.